5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition
Gilead Sciences' (NASDAQ: GILD) executives answered several questions about its pending acquisition of Kite Pharma (NASDAQ: KITE) last week at the Citi biotech conference. However, that discussion didn't include the company's CEO, John Milligan.
Milligan and Gilead's head of hematology and oncology Alessandro Riva faced even tougher questions about the Kite deal at the Morgan Stanley healthcare conference on Monday. Here's how the big biotech's top management team responded to five key questions about the Kite buyout.
Image source: Getty Images.
Source: Fool.com
Citigroup Inc. Aktie
60,66 €
-0,46 %
Klare Kaufstimmung für Citigroup Inc.: Viel mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 73 € für Citigroup Inc. bedeutet eine deutliche Steigerung von über 20% gegenüber dem aktuellen Kurs von 60.66 €.
